Christopher M. Murphy was named Chief Financial Officer of Anaptysbio, Inc, effective May 11, 2026. As of November 6, 2026, Anaptysbio, Inc has reported 2 leadership change filings to the SEC under Item 5.02 of Form 8-K, from April 20, 2026 to May 11, 2026, naming 3 appointments (Form 8-K, May 11, 2026).
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like Anaptysbio, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Anaptysbio, Inc reported changes in 2 filings among its directors and officers to the SEC on Form 8-K, Item 5.02, from 2026-04-20 to 2026-05-11. They name 2 people. Every row below is cited to the filing it comes from, and this page adds each new change as Anaptysbio, Inc files it.
Also on the record for Anaptysbio, Inc
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| August 14, 2026 | Stake report, Schedule 13G/A, by Sirenia Capital Management LP | 5% of the class | 5%+ stakes | Source |
| May 15, 2026 | Stake report, Schedule 13G, by Sirenia Capital Management LP | 6.7% of the class | 5%+ stakes | Source |
| May 15, 2026 | Stake report, Schedule 13G/A, by Point72 Asset Management, L.P. | 0.2% of the class | 5%+ stakes | Source |
| March 26, 2026 | Stake report, Schedule 13G/A, by The Vanguard Group | — | 5%+ stakes | Source |
| February 11, 2026 | Stake report, Schedule 13G/A, by Morgan Stanley | 3.6% of the class | 5%+ stakes | Source |
| January 16, 2026 | Stake report, Schedule 13G/A, by Millennium Management LLC | 2.9% of the class | 5%+ stakes | Source |
| November 14, 2025 | Stake report, Schedule 13G/A, by Mathew P. Arens | 3.12% of the class | 5%+ stakes | Source |
| November 12, 2025 | Stake report, Schedule 13G/A, by THE GOLDMAN SACHS GROUP, INC. | 4.5% of the class | 5%+ stakes | Source |
| September 23, 2025 | Stake report, Schedule 13G, by Millennium Management LLC | 5.1% of the class | 5%+ stakes | Source |
| August 7, 2025 | Stake report, Schedule 13G/A, by Mathew P. Arens | 7.71% of the class | 5%+ stakes | Source |
| August 5, 2025 | Stake report, Schedule 13G, by Morgan Stanley | 6.3% of the class | 5%+ stakes | Source |
| July 29, 2025 | Stake report, Schedule 13G, by The Vanguard Group | 5.23% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs Anaptysbio, Inc now and the warning signs.
Free to see. No signup.
Keep reading
More on Anaptysbio, Inc and the records around it.
Anaptysbio, Inc elsewhere on the record
- 5%+ stake filings Aug 2026
- Who owns it
Companies that share a holder
- First Light Asset Management, LLC also filed stake reports on 12 other companies: NeuroPace Inc (Sep 2026), Neogenomics, Inc. (Aug 2026), PALVELLA THERAPEUTICS, INC. (Aug 2026)
- Sirenia Capital Management LP also filed stake reports on 19 other companies: Alto Neuroscience, Inc. (Aug 2026), CYBIN INC. (Aug 2026), Design Therapeutics, Inc. (Aug 2026)
- Point72 Asset Management, L.P. also filed stake reports on 90 other companies: Immunocore Holdings plc (Nov 2026), Target Hospitality Corp. (Nov 2026), E.W. SCRIPPS Co (Oct 2026)
Watch Anaptysbio, Inc
Get an email when Anaptysbio, Inc files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Anaptysbio, Inc?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Anaptysbio, Inc: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Anaptysbio, Inc covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
14 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-05-11 | In | Chief Financial Officer | 2026-05-11 | 8-K, 2026-05-11 | |
| 2026-05-11 | In | 8-K, 2026-05-11 | |||
| 2026-05-11 | In | Director | 2026-05-11 | 8-K, 2026-05-11 | |
| 2026-04-20 | Reported | not named in the filing | 8-K, 2026-04-20 |
Who leads Anaptysbio, Inc, as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Director: Owen Hughes, appointed, effective 2026-05-11 (filed 2026-05-11).
- Chief Financial Officer: Christopher M. Murphy, appointed, effective 2026-05-11 (filed 2026-05-11).
New leaders reset buying decisions — get the Full Report on Anaptysbio, Inc: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Chief Financial Officer at Anaptysbio, Inc, with the record behind each one.
Find candidates like Chief Financial Officer at Anaptysbio, IncEvery change, in the filing's words
Appointed: Christopher M. Murphy, Chief Financial Officer, effective 2026-05-11
On May 11, 2026, AnaptysBio, Inc. (the "Company") announced that its Board of Directors (the "Board") appointed Christopher M. Murphy as Chief Financial Officer, effective as of May 11, 2026.
Appointed: Christopher M. Murphy
Mr. Murphy will serve as an independent contractor.
Appointed: Owen Hughes, Director, effective 2026-05-11
On May 8, 2026, the Board appointed Owen Hughes as a Class I director, effective May 11, 2026.
- Mr. Murphy previously served as Chief Financial Officer for Third Harmonic Bio, Inc. from January 2024 to December 2025.
- Prior to Horizon, Mr. Murphy held positions of increasing responsibility in the Life Sciences Investment Banking Group at JMP Securities LLC ("JMP") from July 2008 to March 2014, serving most recently as a Director from February 2014 to March 2014.
- Prior to JMP, Mr. Murphy served as a Consultant in the Litigation and Investigation Group of Navigant Consulting, Inc. from July 2006 to June 2008.
- Mr. Murphy holds a B.B.A. in Finance from the University of Notre Dame.
- The Company has entered into a consulting agreement with Mr. Murphy (the "Murphy Consulting Agreement"), which sets forth the principal terms and conditions of his engagement as the Company's Chief Financial Officer.
- The Murphy Consulting Agreement provides for monthly consulting fees of $42,916.66 and an annual target cash bonus opportunity of up to 40% of his total annual consulting fees (the "Bonus"), which Bonus may be earned based upon the achievement of certain performance goals established by the Board (and which will be prorated for any partial year of service).
- Mr. Murphy will also receive an equity grant worth $1,750,000 consisting of restricted stock units (the "Equity Award").
Reported
Board Departures In connection with the Spin-Off, each of Dennis Fenton, Rita Jain and Magda Marquet resigned from the board of directors of the Company, effective as of April 20, 2026, and J. Anthony Ware resigned from the board of directors of the Company, effective as of April 23, 2026.
- Executive Officer Transitions In connection with the Spin-Off, effective as of April 20, 2026, Paul Lizzul, M.D., Ph.D. ceased his role as Chief Medical Officer of the Company.
- Effective as of April 20, 2026, Mr. Lizzul entered into an employment agreement with First Tracks Biotherapeutics as its Chief Medical Officer.
- On April 20, 2026, the Company entered into a consulting agreement with Daniel Faga, the President and Chief Executive Officer of the Company, (the "Faga Consulting Agreement"), pursuant to which Mr. Faga will be engaged as a consultant to serve as Chief Executive Officer of the Company at least through January 15, 2027.
- Mr. Faga's outstanding equity awards will continue vesting pursuant to their terms during his consultancy, and Mr. Faga remains eligible for accelerated vesting in the event he is terminated prior to January 15, 2027.
- As previously disclosed, each of Dennis Mulroy and Eric Loumeau's separation from the Company became effective as of April 20, 2026.
Tools for this story
Each opens in a new tab, filled in for Anaptysbio, Inc. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.